TAGRISSO™▼ (osimertinib)
TAGRISSO is an EGFR TKI indicated as a monotherapy for:
Second-line TAGRISSO
For patients initiated on a TKI other than osimertinib in the 1L setting, some may be suitable for 2L Tagrisso
The T790M mutation
Most patients who receive first/second-generation EGFR TKIs as 1L treatment progress after 9–14 months.6 In up to 60% of these patients, the acquired resistance is driven by a T790M mutation.6-8
TAGRISSO selectively targets both EGFRm and EGFR T790M resistance mutations.1
